Document is current
Any future updates will be listed below
-
Authors
Kick, Anastas https://orcid.org/0009-0001-8132-8299
M’Rabet-Bensalah, Khadija https://orcid.org/0009-0001-5794-2184
Acquistapace, Flavio
Amadid, Hanan https://orcid.org/0000-0001-5759-4960
Ambühl, Robert A.
Braae, Uffe Christian https://orcid.org/0000-0002-2743-4584
Item, Flurin https://orcid.org/0009-0007-2412-2757
Schultes, Bernd https://orcid.org/0000-0002-5301-1163
Züger, Thomas https://orcid.org/0000-0001-6190-7405
Rudofsky, Gottfried https://orcid.org/0000-0002-2576-7190
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04537624 at ClinicalTrials.govDocuments that mention this clinical trial
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study
https://doi.org/10.1007/s13300-023-01525-y
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
https://doi.org/10.1007/s13300-024-01668-6
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S
- License Information
-
More Information
Article History
Received: 7 November 2023
Accepted: 14 December 2023
First Online: 19 January 2024
Declarations
:
: Anastas Kick: no conflicts to disclose. Flavio Acquistapace: no conflicts to disclose. Robert A. Ambühl: no conflicts to disclose. Bernd Schultes: Bernd Schultes has received presentation fees from and compensation as a member of a scientific advisory board of Novo Nordisk and Eli Lilly, as well as for serving as a study investigator for Novo Nordisk. Thomas Züger: no conflicts to disclose. Gottfried Rudofsky: no conflicts to disclose. Khadija M'Rabet-Bensalah, Hanan Amadid, Flurin Item and Uffe Christian Braae are employees of and shareholders in Novo Nordisk.
: The study protocol was approved by the appropriate health authorities according to local guidelines and by an Institutional Review Board/Independent Ethics Committee. The Ethics Committees included: Ethikkommission der Nordwest-und Zentralschweiz (EKNZ), Ethikkommission Zurich, Ethikkommission Ostschweiz (EKOS), Kantonale Ethikkommission Bern (KEK-Bern) and Commission cantonale (VD) d'éthique de la recherche sur l'être humain, Comitato etico cantonale Ticino. The study was conducted in accordance with the Declaration of Helsinki and International Council on Harmonisation Good Clinical Practice guidelines. Participants provided written informed consent prior to commencement of any study-related activity. The study is registered with ClinicalTrials.gov (NCT04537624).
